Published in Proc Natl Acad Sci U S A on February 24, 2003
Genetic animal models of Parkinson's disease. Neuron (2010) 3.86
Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein. Am J Hum Genet (2008) 3.27
Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci (2008) 2.20
Lewy bodies. Proc Natl Acad Sci U S A (2006) 2.15
alpha-Synuclein and neuronal cell death. Mol Neurodegener (2009) 1.85
Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease. Proc Natl Acad Sci U S A (2004) 1.70
Priorities in Parkinson's disease research. Nat Rev Drug Discov (2011) 1.66
Molecular mechanisms of alpha-synuclein neurodegeneration. Biochim Biophys Acta (2008) 1.51
Animal models of Parkinson's disease: a source of novel treatments and clues to the cause of the disease. Br J Pharmacol (2011) 1.39
Hsp104 antagonizes alpha-synuclein aggregation and reduces dopaminergic degeneration in a rat model of Parkinson disease. J Clin Invest (2008) 1.38
SNCA triplication Parkinson's patient's iPSC-derived DA neurons accumulate α-synuclein and are susceptible to oxidative stress. PLoS One (2011) 1.37
Microglia acquire distinct activation profiles depending on the degree of alpha-synuclein neuropathology in a rAAV based model of Parkinson's disease. PLoS One (2010) 1.29
Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain (2012) 1.22
Adeno-associated virus vectors: potential applications for cancer gene therapy. Cancer Gene Ther (2005) 1.19
Parthanatos mediates AIMP2-activated age-dependent dopaminergic neuronal loss. Nat Neurosci (2013) 1.18
Parkinson's disease: animal models and dopaminergic cell vulnerability. Front Neuroanat (2014) 1.18
Animal models of Parkinson's disease: limits and relevance to neuroprotection studies. Mov Disord (2012) 1.17
Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther (2009) 1.14
Drosophila histone deacetylase 6 protects dopaminergic neurons against {alpha}-synuclein toxicity by promoting inclusion formation. Mol Biol Cell (2010) 1.10
Early Parkinson's disease symptoms in α-synuclein transgenic monkeys. Hum Mol Genet (2014) 1.10
Animal models of Parkinson's disease: vertebrate genetics. Cold Spring Harb Perspect Med (2012) 1.08
Mechanisms in dominant parkinsonism: The toxic triangle of LRRK2, alpha-synuclein, and tau. Bioessays (2010) 1.06
Molecular pathology of the fibroblast growth factor family. Hum Mutat (2009) 1.06
Value of genetic models in understanding the cause and mechanisms of Parkinson's disease. Curr Neurol Neurosci Rep (2008) 1.06
Novel rat Alzheimer's disease models based on AAV-mediated gene transfer to selectively increase hippocampal Abeta levels. Mol Neurodegener (2007) 1.06
An α-synuclein AAV gene silencing vector ameliorates a behavioral deficit in a rat model of Parkinson's disease, but displays toxicity in dopamine neurons. Brain Res (2011) 1.05
Toxin-induced and genetic animal models of Parkinson's disease. Parkinsons Dis (2010) 1.04
Oral N-acetyl-cysteine attenuates loss of dopaminergic terminals in alpha-synuclein overexpressing mice. PLoS One (2010) 1.01
Resistance to MPTP-neurotoxicity in α-synuclein knockout mice is complemented by human α-synuclein and associated with increased β-synuclein and Akt activation. PLoS One (2011) 1.00
rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration. Mol Neurodegener (2013) 1.00
Large animal models are critical for rationally advancing regenerative therapies. Regen Med (2006) 1.00
Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration. J Biol Chem (2015) 1.00
Definition of a molecular pathway mediating α-synuclein neurotoxicity. J Neurosci (2015) 0.99
A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol Cell Neurosci (2010) 0.98
Neuronal gene expression correlates of Parkinson's disease with dementia. Mov Disord (2008) 0.96
Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson's disease produced by decreasing doses of alpha-synuclein. PLoS One (2011) 0.96
Innate inflammation in Parkinson's disease. Cold Spring Harb Perspect Med (2012) 0.96
Large animal models of neurological disorders for gene therapy. ILAR J (2009) 0.95
Parkinson's disease: a rethink of rodent models. Exp Brain Res (2006) 0.95
Protein oxidative modifications in the ageing brain: consequence for the onset of neurodegenerative disease. Free Radic Res (2010) 0.93
Propagation of alpha-synuclein pathology: hypotheses, discoveries, and yet unresolved questions from experimental and human brain studies. Acta Neuropathol (2015) 0.92
α-Synuclein and neuronal cell death. Mol Neurobiol (2012) 0.92
The impact of genetic research on our understanding of Parkinson's disease. Prog Brain Res (2010) 0.90
M1 and M2 immune activation in Parkinson's Disease: Foe and ally? Neuroscience (2014) 0.90
Direct detection of alpha synuclein oligomers in vivo. Acta Neuropathol Commun (2013) 0.89
Modeling Parkinson's disease using induced pluripotent stem cells. Curr Neurol Neurosci Rep (2012) 0.89
Genetic strategies to study TDP-43 in rodents and to develop preclinical therapeutics for amyotrophic lateral sclerosis. Eur J Neurosci (2011) 0.88
Quantitative proteomics of a presymptomatic A53T alpha-synuclein Drosophila model of Parkinson disease. Mol Cell Proteomics (2008) 0.88
Molecular insights into Parkinson's disease. F1000 Med Rep (2011) 0.87
Neurodegenerative disorders: Parkinson's disease and Huntington's disease. J Neurol Neurosurg Psychiatry (2005) 0.87
A microRNA embedded AAV α-synuclein gene silencing vector for dopaminergic neurons. Brain Res (2011) 0.86
Loss of functional alpha-synuclein: a toxic event in Parkinson's disease? J Parkinsons Dis (2012) 0.86
Efficient gene delivery and selective transduction of astrocytes in the mammalian brain using viral vectors. Front Cell Neurosci (2013) 0.86
The contribution of alpha synuclein to neuronal survival and function - Implications for Parkinson's disease. J Neurochem (2016) 0.85
Domain a' of protein disulfide isomerase plays key role in inhibiting alpha-synuclein fibril formation. Cell Stress Chaperones (2009) 0.84
Proteome response to the panneural expression of human wild-type alpha-synuclein: a Drosophila model of Parkinson's disease. J Proteome Res (2008) 0.82
Alpha synuclein is transported into and out of the brain by the blood-brain barrier. Peptides (2014) 0.81
Comparative analysis of different peptidyl-prolyl isomerases reveals FK506-binding protein 12 as the most potent enhancer of alpha-synuclein aggregation. J Biol Chem (2011) 0.81
Targeting alpha-synuclein with a microRNA-embedded silencing vector in the rat substantia nigra: positive and negative effects. Brain Res (2014) 0.81
Characterization of cognitive deficits in rats overexpressing human alpha-synuclein in the ventral tegmental area and medial septum using recombinant adeno-associated viral vectors. PLoS One (2013) 0.81
Mechanisms of alpha-synuclein action on neurotransmission: cell-autonomous and non-cell autonomous role. Biomolecules (2015) 0.81
Up-regulation of SNCA gene expression: implications to synucleinopathies. Neurogenetics (2016) 0.80
Versatile somatic gene transfer for modeling neurodegenerative diseases. Neurotox Res (2009) 0.80
Drug Targeting of alpha-Synuclein Oligomerization in Synucleinopathies. Perspect Medicin Chem (2008) 0.80
PET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson's disease. PLoS One (2012) 0.80
Comparative Analysis of the Effects of Neurotrophic Factors CDNF and GDNF in a Nonhuman Primate Model of Parkinson's Disease. PLoS One (2016) 0.79
Targeted Overexpression of α-Synuclein by rAAV2/1 Vectors Induces Progressive Nigrostriatal Degeneration and Increases Vulnerability to MPTP in Mouse. PLoS One (2015) 0.79
ASIP Outstanding Investigator Award Lecture. New approaches to the pathology and genetics of neurodegeneration. Am J Pathol (2010) 0.79
Selective neuronal vulnerability in Parkinson disease. Nat Rev Neurosci (2017) 0.79
Brain disposition of α-Synuclein: roles of brain barrier systems and implications for Parkinson's disease. Fluids Barriers CNS (2014) 0.78
Robust Long-term Transduction of Common Marmoset Neuromuscular Tissue With rAAV1 and rAAV9. Mol Ther Nucleic Acids (2013) 0.77
Development of Nonviral Vectors Targeting the Brain as a Therapeutic Approach For Parkinson's Disease and Other Brain Disorders. Mol Ther (2015) 0.77
Gene therapy for misfolding protein diseases of the central nervous system. Neurotherapeutics (2013) 0.77
AAV's Golden Jubilee. Mol Ther (2015) 0.77
Excess α-synuclein worsens disease in mice lacking ubiquitin carboxy-terminal hydrolase L1. Sci Rep (2012) 0.77
Lentiviral vector-mediated overexpression of mutant ataxin-7 recapitulates SCA7 pathology and promotes accumulation of the FUS/TLS and MBNL1 RNA-binding proteins. Mol Neurodegener (2016) 0.77
Porcine synapsin 1: SYN1 gene analysis and functional characterization of the promoter. FEBS Open Bio (2013) 0.75
Role of microRNAs in the Regulation of α-Synuclein Expression: A Systematic Review. Front Mol Neurosci (2016) 0.75
α-Synuclein and nonhuman primate models of Parkinson's disease. J Neurosci Methods (2015) 0.75
AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease. Acta Neuropathol Commun (2017) 0.75
Lentiviral vectors for the central nervous system. MedGenMed (2004) 0.75
Magnetic resonance imaging and tensor-based morphometry in the MPTP non-human primate model of Parkinson's disease. PLoS One (2017) 0.75
Animal models of α-synucleinopathy for Parkinson disease drug development. Nat Rev Neurosci (2017) 0.75
Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science (1997) 28.30
Alpha-synuclein in Lewy bodies. Nature (1997) 20.83
Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet (1998) 12.92
Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci (2000) 10.62
Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther (1999) 7.96
A Drosophila model of Parkinson's disease. Nature (2000) 7.82
Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science (2000) 6.28
Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol (1996) 6.22
Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci (2001) 5.32
Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci (1999) 5.15
Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron (2002) 4.77
Adeno-associated virus general transduction vectors: analysis of proviral structures. J Virol (1988) 4.64
Kinetic stabilization of the alpha-synuclein protofibril by a dopamine-alpha-synuclein adduct. Science (2001) 4.48
Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci U S A (2002) 3.33
Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease. Nat Med (2002) 3.31
Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci (2002) 3.12
alpha -Synucleinopathy and selective dopaminergic neuron loss in a rat lentiviral-based model of Parkinson's disease. Proc Natl Acad Sci U S A (2002) 2.81
Subcellular localization of wild-type and Parkinson's disease-associated mutant alpha -synuclein in human and transgenic mouse brain. J Neurosci (2000) 2.49
alpha-Synuclein shares physical and functional homology with 14-3-3 proteins. J Neurosci (1999) 2.25
Neuropathology in mice expressing human alpha-synuclein. J Neurosci (2000) 2.06
Experimental models of Parkinson's disease. Nat Rev Neurosci (2001) 2.06
Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci (2001) 2.04
A panel of epitope-specific antibodies detects protein domains distributed throughout human alpha-synuclein in Lewy bodies of Parkinson's disease. J Neurosci Res (2000) 1.97
Adeno-associated virus-mediated gene transfer to the brain: duration and modulation of expression. Hum Gene Ther (1999) 1.67
Production and purification of recombinant adeno-associated virus. Methods Enzymol (2000) 1.66
Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res (2000) 1.53
CMV-beta-actin promoter directs higher expression from an adeno-associated viral vector in the liver than the cytomegalovirus or elongation factor 1 alpha promoter and results in therapeutic levels of human factor X in mice. Hum Gene Ther (2001) 1.49
Lack of nigral pathology in transgenic mice expressing human alpha-synuclein driven by the tyrosine hydroxylase promoter. Neurobiol Dis (2001) 1.48
Animal models of PD: pieces of the same puzzle? Neuron (2002) 1.34
Human alpha-synuclein over-expression increases intracellular reactive oxygen species levels and susceptibility to dopamine. Neurosci Lett (2002) 1.23
Oxidative post-translational modifications of alpha-synuclein in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease. J Neurochem (2001) 1.20
Enhanced vulnerability to oxidative stress by alpha-synuclein mutations and C-terminal truncation. Neuroscience (2000) 1.17
Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity. Hum Mol Genet (2000) 1.17
Sensitivity to MPTP is not increased in Parkinson's disease-associated mutant alpha-synuclein transgenic mice. J Neurochem (2001) 0.98
Behavioural analysis of unilateral monoamine depletion in the marmoset. Brain (1992) 0.93
Progress in direct striatal delivery of L-dopa via gene therapy for treatment of Parkinson's disease using recombinant adeno-associated viral vectors. Exp Neurol (1999) 0.91
Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol (2006) 7.32
Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation. Nat Med (2008) 6.90
Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods (2002) 5.30
Direct conversion of human fibroblasts to dopaminergic neurons. Proc Natl Acad Sci U S A (2011) 4.81
Next generation of adeno-associated virus 2 vectors: point mutations in tyrosines lead to high-efficiency transduction at lower doses. Proc Natl Acad Sci U S A (2008) 3.84
TFEB-mediated autophagy rescues midbrain dopamine neurons from α-synuclein toxicity. Proc Natl Acad Sci U S A (2013) 3.33
Parkinson-like neurodegeneration induced by targeted overexpression of alpha-synuclein in the nigrostriatal system. J Neurosci (2002) 3.12
Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding. J Virol (2003) 2.93
Generation of induced neurons via direct conversion in vivo. Proc Natl Acad Sci U S A (2013) 2.51
Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in parkinsonian rats. Brain (2007) 2.49
Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington's disease transgenic mice. Mol Ther (2005) 2.47
Restoration of visual function in P23H rhodopsin transgenic rats by gene delivery of BiP/Grp78. Proc Natl Acad Sci U S A (2010) 2.40
Myeloid and lymphoid contribution to non-haematopoietic lineages through irradiation-induced heterotypic cell fusion. Nat Cell Biol (2008) 2.17
Structure of adeno-associated virus serotype 8, a gene therapy vector. J Virol (2007) 2.15
Circulating anti-wild-type adeno-associated virus type 2 (AAV2) antibodies inhibit recombinant AAV2 (rAAV2)-mediated, but not rAAV5-mediated, gene transfer in the brain. J Virol (2004) 2.12
Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain (2005) 2.06
The phosphorylation state of Ser-129 in human alpha-synuclein determines neurodegeneration in a rat model of Parkinson disease. Proc Natl Acad Sci U S A (2008) 2.00
Structurally mapping the diverse phenotype of adeno-associated virus serotype 4. J Virol (2006) 1.97
Tyrosine-phosphorylation of AAV2 vectors and its consequences on viral intracellular trafficking and transgene expression. Virology (2008) 1.96
Cell therapy in Parkinson's disease. NeuroRx (2004) 1.93
Nurr1 is required for maintenance of maturing and adult midbrain dopamine neurons. J Neurosci (2009) 1.89
Phase I trial of intramuscular injection of a recombinant adeno-associated virus serotype 2 alphal-antitrypsin (AAT) vector in AAT-deficient adults. Hum Gene Ther (2006) 1.83
Adenovirus-facilitated nuclear translocation of adeno-associated virus type 2. J Virol (2002) 1.77
Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci (2002) 1.74
Recombinant adeno-associated viral vector (rAAV) delivery of GDNF provides protection against 6-OHDA lesion in the common marmoset monkey (Callithrix jacchus). Exp Neurol (2003) 1.72
Fetal dopaminergic transplantation trials and the future of neural grafting in Parkinson's disease. Lancet Neurol (2013) 1.72
Adeno-associated virus type 2 VP2 capsid protein is nonessential and can tolerate large peptide insertions at its N terminus. J Virol (2004) 1.67
Time course of transgene expression after intrastriatal pseudotyped rAAV2/1, rAAV2/2, rAAV2/5, and rAAV2/8 transduction in the rat. Mol Ther (2007) 1.67
Identification of dopaminergic neurons of nigral and ventral tegmental area subtypes in grafts of fetal ventral mesencephalon based on cell morphology, protein expression, and efferent projections. J Neurosci (2005) 1.67
Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat Neurosci (2004) 1.61
Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson's disease in marmoset monkeys. Exp Neurol (2003) 1.59
Efficient production of mesencephalic dopamine neurons by Lmx1a expression in embryonic stem cells. Proc Natl Acad Sci U S A (2009) 1.57
Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: the role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr Gene Ther (2007) 1.55
Recombinant adeno-associated viral vectors as therapeutic agents to treat neurological disorders. Mol Ther (2006) 1.54
L-DOPA-induced dyskinesia in the intrastriatal 6-hydroxydopamine model of parkinson's disease: relation to motor and cellular parameters of nigrostriatal function. Neurobiol Dis (2002) 1.54
Nigrostriatal rAAV-mediated GDNF overexpression induces robust weight loss in a rat model of age-related obesity. Mol Ther (2009) 1.52
Cell transplantation in Parkinson's disease: how can we make it work? Trends Neurosci (2005) 1.51
Myosin IIb regulates actin dynamics during synaptic plasticity and memory formation. Neuron (2010) 1.49
Structure of adeno-associated virus type 4. J Virol (2005) 1.47
Reduced juvenile long-term depression in tuberous sclerosis complex is mitigated in adults by compensatory recruitment of mGluR5 and Erk signaling. PLoS Biol (2013) 1.47
Characterization of Lewy body pathology in 12- and 16-year-old intrastriatal mesencephalic grafts surviving in a patient with Parkinson's disease. Mov Disord (2010) 1.47
Recombinant adeno-associated viral vectors in the nervous system. Hum Gene Ther (2005) 1.46
Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain (2007) 1.45
Heparin binding induces conformational changes in Adeno-associated virus serotype 2. J Struct Biol (2008) 1.44
Neonatal intraperitoneal or intravenous injections of recombinant adeno-associated virus type 8 transduce dorsal root ganglia and lower motor neurons. Hum Gene Ther (2008) 1.42
Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson's disease. J Neurosci (2007) 1.42
α-Synuclein-induced down-regulation of Nurr1 disrupts GDNF signaling in nigral dopamine neurons. Sci Transl Med (2012) 1.40
Impaired neurotransmission caused by overexpression of α-synuclein in nigral dopamine neurons. Proc Natl Acad Sci U S A (2012) 1.40
GDNF fails to exert neuroprotection in a rat α-synuclein model of Parkinson's disease. Brain (2011) 1.38
Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virus. Anticancer Res (2003) 1.35
Cell therapeutics in Parkinson's disease. Neurotherapeutics (2011) 1.32
Migration patterns and phenotypic differentiation of long-term expanded human neural progenitor cells after transplantation into the adult rat brain. Brain Res Dev Brain Res (2002) 1.32
Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. Mol Ther (2005) 1.30
AAV9: a potential blood-brain barrier buster. Mol Ther (2009) 1.30
In vivo RNAi-mediated alpha-synuclein silencing induces nigrostriatal degeneration. Mol Ther (2010) 1.26
Metabolic regulation of neuronal plasticity by the energy sensor AMPK. PLoS One (2010) 1.25
Glucose regulated protein 78 diminishes α-synuclein neurotoxicity in a rat model of Parkinson disease. Mol Ther (2012) 1.24
Overexpression of glial cell line-derived neurotrophic factor using a lentiviral vector induces time- and dose-dependent downregulation of tyrosine hydroxylase in the intact nigrostriatal dopamine system. J Neurosci (2004) 1.23
Systemic mannitol-induced hyperosmolality amplifies rAAV2-mediated striatal transduction to a greater extent than local co-infusion. Mol Ther (2005) 1.22
Maternal and fetal outcomes if gestational impaired glucose tolerance is not treated. Diabetes Care (2003) 1.21
Transplantation of human neural progenitor cells into the neonatal rat brain: extensive migration and differentiation with long-distance axonal projections. Exp Neurol (2002) 1.20
Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain (2008) 1.19
Structural insight into the unique properties of adeno-associated virus serotype 9. J Virol (2012) 1.18
Adeno-associated viral (AAV) serotype 5 vector mediated gene delivery of endothelin-converting enzyme reduces Abeta deposits in APP + PS1 transgenic mice. Mol Ther (2008) 1.17
Production, purification, crystallization and preliminary X-ray structural studies of adeno-associated virus serotype 5. Acta Crystallogr Sect F Struct Biol Cryst Commun (2005) 1.17
Clinical trials in neurological disorders using AAV vectors: promises and challenges. Curr Opin Mol Ther (2004) 1.16
Alpha-synuclein cell-to-cell transfer and seeding in grafted dopaminergic neurons in vivo. PLoS One (2012) 1.15
Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice. PLoS One (2011) 1.15
In vitro characterization of a human neural progenitor cell coexpressing SSEA4 and CD133. J Neurosci Res (2007) 1.15
Differential transduction following basal ganglia administration of distinct pseudotyped AAV capsid serotypes in nonhuman primates. Mol Ther (2009) 1.14
Changes in transcription within the CA1 field of the hippocampus are associated with age-related spatial learning impairments. Neurobiol Learn Mem (2006) 1.14
Patterns of gene expression reveal a temporally orchestrated wound healing response in the injured spinal cord. J Neurosci (2004) 1.13
Identification of cellular proteins that interact with the adeno-associated virus rep protein. J Virol (2008) 1.12
Production, purification and preliminary X-ray crystallographic studies of adeno-associated virus serotype 1. Acta Crystallogr Sect F Struct Biol Cryst Commun (2006) 1.12
Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. Eur J Neurosci (2009) 1.11
Altered longevity-assurance activity of p53:p44 in the mouse causes memory loss, neurodegeneration and premature death. Aging Cell (2010) 1.11
Transcription factor Nurr1 maintains fiber integrity and nuclear-encoded mitochondrial gene expression in dopamine neurons. Proc Natl Acad Sci U S A (2013) 1.09